Mustang Bio Appoints Sadik Kassim CSO, Knut Niss Named CTO

Cancer immunotherapy developer Mustang Bio (NASDAQ: [[ticker:MBIO]]) has promoted Sadik Kassim to chief scientific officer. Kassim joined New York-based Mustang last year as vice president of process and analytical development. He came to Mustang from Novartis (NYSE: [[ticker:NVS]]), where he was head of analytical development. Mustang also promoted Knut Niss to chief technology officer. Niss joined the company last year as vice president of operations. He previously worked at Biogen (NASDAQ: [[ticker:BIIB]]) as cell therapy asset leader. Mustang’s pipeline includes two drugs in Phase 1 studies, MB-101 for glioblastoma and MB-102 for acute myeloid leukemia.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan